The introduction of DAAs has caused a significant reduction in the percentage of liver transplant recipients for HCV who are viremic after surgery.
Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.
Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.
The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.
A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.
Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.
Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
Immunosuppressive agents do not increase the risk of HCV flares in anti-HCV-positive lupus patients.
Daclatasvir plus sofosbuvir demonstrated a sustained virological response in 98% of patients with genotype 1 hepatitis C infection.
The risk-benefit profile of more widespread hepatitis C screening is not sufficiently understood, researchers suggest.
Researchers have eliminated hepatitis C as the cause of impaired mental function in HIV patients.
Combination simeprevir and sofosbuvir has been approved by the FDA for treatment of chronic genotype 1 hepatitis C.
Fatty liver disease and other topics gained traction at the AASLD Annual Meeting as HCV therapy research plateaus.